CALL/NOVO-NORDISK B/1500/0.1/21.03.25 | Market Closed - BOERSE MUENCHEN 15:25:23 28/05/2024 BST | ||
| 0.248 EUR | -5.34% |
|
| Current month | -16.22% | ||
| 1 month | +3.33% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 28/05/24 | 0.248 | -5.34% |
| 27/05/24 | 0.262 | -5.42% |
| 24/05/24 | 0.277 | +10.36% |
| 23/05/24 | 0.251 | +0.40% |
| 22/05/24 | 0.25 | +5.04% |
Real-time BOERSE MUENCHEN
Last update May 28, 2024 at 03:25 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Goldman Sachs |
| WKN | GG563N |
| ISIN | DE000GG563N7 |
| Date issued | 12/03/2024 |
| Strike | 1,500 kr |
| Maturity | 21/03/2025 (297 Days) |
| Parity | 10 : 1 |
| Emission price | 0.18 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.441 € |
|---|---|
| Lowest since issue | 0.209 € |
| Spread | 0.03 € |
| Spread % | 11.11% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
915.7
DKK
Average target price
909.2
DKK
Spread / Average Target
-0.71%
- Stock Market
- Warrants
- Warrant
